A Phase I/II Study of DS-3201b and Irinotecan for Patients with Recurrent Small Cell Lung Cancer


Full Title

A Phase I/II Study of DS-3201b, an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small Cell Lung Cancer


Irinotecan is a standard chemotherapy drug used to treat small cell lung cancer (SCLC). The main purpose of this study is to find the highest dose of the investigational drug DS-3201b that can be given in combination with irinotecan in patients with SCLC that came back or grew further after standard treatment. A secondary purpose of this study is to determine whether DS-3201b, when given with irinotecan, is effective for controlling SCLC.

DS-3201b works by blocking the activity of two proteins called EZH1 and EZH2, which are involved in cancer growth. Blocking EZH1 and EZH2 is thought to help standard chemotherapy, such as irinotecan, work more effectively against SCLC. DS-3201b is taken orally (by mouth) and irinotecan is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have SCLC that came back despite prior treatment with platinum-based chemotherapy.
  • At least 2 weeks must pass between completion of previous therapies and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Victoria Lai at 646-609-3793.






Disease Status

Relapsed or Refractory